APM
GPCR icon

Avidity Partners Management’s Structure Therapeutics GPCR Stock Holding History

Avidity Partners Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-150,000
Closed -$6.43M – 96
2024
Q1 		$6.43M Sell
150,000
-450,000
-75% -$19M 0.21% 74
2023
Q4 		$24.5M Buy
+600,000
New +$34.4M 0.89% 44

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Avidity Partners Management's GPCR Position: Q2 2026 in Review

Avidity Partners Management increased its Structure Therapeutics (GPCR) stake by 227% in Q2 2026, buying an estimated $3.01M and bringing the position to 98,000 shares worth $5.26M. The position accounts for 0.84% of the portfolio, ranked #19.

Avidity Partners Management first reported a position in GPCR in Q2 2023 and has held it in 8 quarters since. The position peaked at $44M in Q4 2023. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Avidity Partners Management held 98,000 shares of Structure Therapeutics worth $5.26M as of Q2 2026.
  • Avidity Partners Management bought 68,000 Structure Therapeutics shares in Q2 2026, an estimated $3.01M.
  • Structure Therapeutics made up 0.84% of Avidity Partners Management's portfolio in Q2 2026, its #19 holding.
  • Avidity Partners Management first reported a position in Structure Therapeutics in Q2 2023 and has held it in 8 quarters since.
  • Avidity Partners Management's Structure Therapeutics position peaked at $44M in Q4 2023.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.